2017 American Transplant Congress
Longer Ischemic Time Is Associated with Late Graft Dysfunction in Pediatric Heart Transplant Recipients.
1Medical University of South Carolina, Charleston, SC; 2UT Southwestern, Dallas, TX
Introduction: The purpose of this study was to investigate associations between clinical factors and cardiac function as measured by pressure-volume loops (PVL) in a pediatric…2017 American Transplant Congress
Rates of Lost to Follow-Up Among Pediatric Heart, Kidney, and Liver Transplant Recipients.
Background. Pediatric transplant recipients are typically transitioned to adult transplant programs for post-transplant care after age 18. For pediatric kidney (KI) recipients transitioning to adult…2017 American Transplant Congress
Primary Graft Dysfunction Post Heart Transplantation: Is There Greater Risk for De Novo Donor-Specific Antibody Development?
Cedars-Sinai Heart Institute, Los Angeles
Background: Primary graft dysfunction (PGD) may occur in up to 30% of heart transplant recipients and has been associated with increased mortality. The development of…2017 American Transplant Congress
Impact of Dialysis During the Transplant Admission on Transplant and Post-Transplant Cost of Care.
This study examines the impact of dialysis during the transplant admission on total cost of transplant and one year post-transplant care for kidney, liver, and…2017 American Transplant Congress
Alemtuzumab Use in a Single Center Pediatric Heart Transplant Cohort.
Purpose: To describe the use and complications of alemtuzumab (AMB), a CD52 monoclonal antibody, in pediatric heart transplant (HT) patients (pt).Methods: Retrospective chart review of…2017 American Transplant Congress
Time to First Therapeutic Tacrolimus Level: What Impact Does It Have After Heart Transplantation?
University of Pittsburgh Medical Center, Pittsburgh, PA
Purpose: Appropriate time to therapeutic immunosuppression levels is not well defined. The purpose of this study is to investigate outcomes related to time to therapeutic…2017 American Transplant Congress
Exploring Differential Antibody Response to Bortezomib in Heart Transplantation.
Northwestern University, Chicago, IL
Twelve heart transplant candidates (2013-2016) received Bortezomib (BTZ) for desensitization. Differential antibody (Ab) response was observed. BTZ cycles consisted of 4 injections of 1.3 mg/m2;…2017 American Transplant Congress
Impact of mTOR-Inhibition on Tolerance-Induction Following Heart Transplantation.
Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany
Introduction: The mammalian target of rapamycin (mTOR) is a central regulator of the immune system and therefore one target of immunosuppressive drug therapy. Tolerance-inducing properties…2017 American Transplant Congress
Antibody Mediated Rejection and Donor Specific Antibodies in Heart Transplant Patients: Single Center Experience.
BACKGROUND AND AIMS: Preexisting donor specific antibodies (DSA) cause acute antibody mediated rejection (AMR), which can be avoided during pre-transplant work up. Diagnosis and management…2017 American Transplant Congress
Is the Current Heart Allocation System Just and Fair for Blood Type O Recipients? – A Propensity-Matched Analysis of 34353 Patients in the UNOS Registry.
Columbia University Medical Center, New York, NY
Purpose: There is a known disparity between the waiting time on heart transplant (HTx) between blood type O and non-O recipients. This difference is mainly…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 30
- Next Page »